High dose ARA-C as induction therapy of acute myeloid leukaemia. 1990

H Minigo, and D Nemet, and A Planinc-Peraica, and V Bogdanic, and B Labar, and B Jaksic, and E Hauptmann
Department of Medicine Dr. O. Novosel, Medical School, University of Zagreb.

Twenty-one newly diagnosed adult AML patients were treated with high dose Ara-C (HD-ARA-C) as a single induction treatment with the dose of 2 g/m2 q 12 hours x 12. Seventy-six percent (16/21) responded with complete remission. Three patients died in induction in pancytopenia, another one died on day 44 in CR due to bleeding of pulmonary aspergilloma. This treatment seems to be highly efficient for remission induction, but requires an adequate transfusion and other supportive measures. The overall toxicity was transient and seems acceptable. However, the remission duration is unacceptably short, the consolidation with the same treatment seems to be inadequate. More aggressive treatment in postinduction period seems to be warranted.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006410 Hematopoiesis The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY). Hematopoiesis, Medullary,Haematopoiesis,Medullary Hematopoiesis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015470 Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. Leukemia, Myelogenous, Acute,Leukemia, Nonlymphocytic, Acute,Myeloid Leukemia, Acute,Nonlymphocytic Leukemia, Acute,ANLL,Acute Myelogenous Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia with Maturation,Acute Myeloid Leukemia without Maturation,Leukemia, Acute Myelogenous,Leukemia, Acute Myeloid,Leukemia, Myeloblastic, Acute,Leukemia, Myelocytic, Acute,Leukemia, Myeloid, Acute, M1,Leukemia, Myeloid, Acute, M2,Leukemia, Nonlymphoblastic, Acute,Myeloblastic Leukemia, Acute,Myelocytic Leukemia, Acute,Myelogenous Leukemia, Acute,Myeloid Leukemia, Acute, M1,Myeloid Leukemia, Acute, M2,Nonlymphoblastic Leukemia, Acute,Acute Myeloblastic Leukemia,Acute Myeloblastic Leukemias,Acute Myelocytic Leukemia,Acute Myelocytic Leukemias,Acute Myelogenous Leukemias,Acute Myeloid Leukemias,Acute Nonlymphoblastic Leukemia,Acute Nonlymphoblastic Leukemias,Acute Nonlymphocytic Leukemia,Acute Nonlymphocytic Leukemias,Leukemia, Acute Myeloblastic,Leukemia, Acute Myelocytic,Leukemia, Acute Nonlymphoblastic,Leukemia, Acute Nonlymphocytic,Leukemias, Acute Myeloblastic,Leukemias, Acute Myelocytic,Leukemias, Acute Myelogenous,Leukemias, Acute Myeloid,Leukemias, Acute Nonlymphoblastic,Leukemias, Acute Nonlymphocytic,Myeloblastic Leukemias, Acute,Myelocytic Leukemias, Acute,Myelogenous Leukemias, Acute,Myeloid Leukemias, Acute,Nonlymphoblastic Leukemias, Acute,Nonlymphocytic Leukemias, Acute

Related Publications

H Minigo, and D Nemet, and A Planinc-Peraica, and V Bogdanic, and B Labar, and B Jaksic, and E Hauptmann
February 2012, Anticancer research,
H Minigo, and D Nemet, and A Planinc-Peraica, and V Bogdanic, and B Labar, and B Jaksic, and E Hauptmann
February 1983, Cancer,
H Minigo, and D Nemet, and A Planinc-Peraica, and V Bogdanic, and B Labar, and B Jaksic, and E Hauptmann
June 1984, Cancer,
H Minigo, and D Nemet, and A Planinc-Peraica, and V Bogdanic, and B Labar, and B Jaksic, and E Hauptmann
November 1985, British journal of haematology,
H Minigo, and D Nemet, and A Planinc-Peraica, and V Bogdanic, and B Labar, and B Jaksic, and E Hauptmann
January 1985, Haematology and blood transfusion,
H Minigo, and D Nemet, and A Planinc-Peraica, and V Bogdanic, and B Labar, and B Jaksic, and E Hauptmann
May 1982, British journal of haematology,
H Minigo, and D Nemet, and A Planinc-Peraica, and V Bogdanic, and B Labar, and B Jaksic, and E Hauptmann
August 2002, Haematologica,
H Minigo, and D Nemet, and A Planinc-Peraica, and V Bogdanic, and B Labar, and B Jaksic, and E Hauptmann
June 1985, Zhonghua nei ke za zhi,
H Minigo, and D Nemet, and A Planinc-Peraica, and V Bogdanic, and B Labar, and B Jaksic, and E Hauptmann
June 1987, Seminars in oncology,
H Minigo, and D Nemet, and A Planinc-Peraica, and V Bogdanic, and B Labar, and B Jaksic, and E Hauptmann
June 2003, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Copied contents to your clipboard!